While PCSK9 inhibitors have demonstrated efficacy in lowering serum Lp(a) levels and mitigating adverse events associated with PAD, there is a dearth of research on the management of PAD individuals who have increased Lp(a) and insufficient evidence for Lp(a)-specific therapies at this time. The gene discussed is PCSK9; the disease is peripheral arterial disease.